J
Jack A. Roth
Researcher at University of Texas MD Anderson Cancer Center
Publications - 790
Citations - 55408
Jack A. Roth is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 110, co-authored 764 publications receiving 51306 citations. Previous affiliations of Jack A. Roth include University of Texas System & University of Texas at Austin.
Papers
More filters
Journal ArticleDOI
Somatic mutations affect key pathways in lung adenocarcinoma
Li Ding,Gad Getz,David A. Wheeler,Elaine R. Mardis,Michael D. McLellan,Kristian Cibulskis,Carrie Sougnez,Heidi Greulich,Heidi Greulich,Donna M. Muzny,Margaret Morgan,Lucinda Fulton,Robert S. Fulton,Qunyuan Zhang,Michael C. Wendl,Michael S. Lawrence,David E. Larson,Ken Chen,David J. Dooling,Aniko Sabo,Alicia Hawes,Hua Shen,Shalini N. Jhangiani,Lora Lewis,Otis Hall,Yiming Zhu,Tittu Mathew,Yanru Ren,Jiqiang Yao,Steven E. Scherer,Kerstin Clerc,Ginger A. Metcalf,Brian Ng,Aleksandar Milosavljevic,Manuel L. Gonzalez-Garay,John R. Osborne,Rick Meyer,Xiaoqi Shi,Yuzhu Tang,Daniel C. Koboldt,Ling Lin,Rachel Abbott,Tracie L. Miner,Craig Pohl,Ginger A. Fewell,Carrie A. Haipek,Heather Schmidt,Brian H. Dunford-Shore,Aldi T. Kraja,Seth D. Crosby,Christopher S. Sawyer,Tammi L. Vickery,Sacha N. Sander,Jody S. Robinson,Wendy Winckler,Wendy Winckler,Jennifer Baldwin,Lucian R. Chirieac,Amit Dutt,Amit Dutt,Timothy Fennell,Megan Hanna,Megan Hanna,Bruce E. Johnson,Robert C. Onofrio,Roman K. Thomas,Giovanni Tonon,Barbara A. Weir,Barbara A. Weir,Xiaojun Zhao,Xiaojun Zhao,Liuda Ziaugra,Michael C. Zody,Thomas J. Giordano,Mark B. Orringer,Jack A. Roth,Margaret R. Spitz,Ignacio I. Wistuba,Bradley A. Ozenberger,Peter J. Good,Andrew C. Chang,David G. Beer,Mark A. Watson,Marc Ladanyi,Stephen R. Broderick,Akihiko Yoshizawa,William D. Travis,William Pao,Michael A. Province,George M. Weinstock,Harold E. Varmus,Stacey Gabriel,Eric S. Lander,Richard A. Gibbs,Matthew Meyerson,Matthew Meyerson,Richard K. Wilson +96 more
TL;DR: Somatic mutations in primary lung adenocarcinoma for several tumour suppressor genes involved in other cancers and for sequence changes in PTPRD as well as the frequently deleted gene LRP1B are found.
Journal ArticleDOI
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
Hisayuki Shigematsu,Hisayuki Shigematsu,Li Lin,Takao Takahashi,Masaharu Nomura,Makoto Suzuki,Ignacio I. Wistuba,Kwun M. Fong,Huei Lee,Shinichi Toyooka,Nobuyoshi Shimizu,Takehiko Fujisawa,Ziding Feng,Jack A. Roth,Joachim Herz,John D. Minna,Adi F. Gazdar +16 more
TL;DR: EGFR TK domain mutations are the first molecular change known to occur specifically in never smokers, and can lead to lung cancer pathogenesis.
Journal ArticleDOI
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer
David P. Kelsen,Robert J. Ginsberg,Thomas F. Pajak,Daniel G. Sheahan,Leonard L. Gunderson,Joanne E. Mortimer,Norman C. Estes,Daniel G. Haller,Jaffer A. Ajani,Walter Kocha,Bruce D. Minsky,Jack A. Roth +11 more
TL;DR: Preoperative chemotherapy with a combination of cisplatin and fluorouracil did not improve overall survival among patients with epidermoid cancer or adenocarcinoma of the esophagus.
Journal ArticleDOI
Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials
Joe Y. Chang,Suresh Senan,Marinus A. Paul,Reza J. Mehran,Alexander V. Louie,Peter A Balter,Harry J.M. Groen,Stephen E. McRae,Joachim Widder,Lei Feng,Ben E. E. M. van den Borne,Mark F. Munsell,Coen W. Hurkmans,Donald A. Berry,Erik van Werkhoven,John J. Kresl,Anne-Marie C. Dingemans,Omar Dawood,Cornelis J.A. Haasbeek,Larry S. Carpenter,Katrien De Jaeger,Ritsuko Komaki,Ben J. Slotman,Egbert F. Smit,Jack A. Roth +24 more
TL;DR: Overall survival for SABR versus surgery by pooling data from the STARS and ROSEL trials was 95% (95% CI 85-100) in the S ABR group compared with 79% in the surgery group, and recurrence-free survival at 3 years was 86% ( 95% CI 74-100).
Journal Article
BRAF and RAS mutations in human lung cancer and melanoma
Marcia S. Brose,Patricia Volpe,Michael Feldman,Madhu S. Kumar,Irum Rishi,Renee M. Gerrero,Eugene Einhorn,Meenhard Herlyn,John D. Minna,Andrew G. Nicholson,Jack A. Roth,Steven M. Albelda,Helen Davies,Charles Cox,Graham Brignell,Philip J. Stephens,P. Andrew Futreal,Richard Wooster,Michael R. Stratton,Barbara L. Weber +19 more
TL;DR: Three BRAF mutations identified in this study are novel, altering residues important in AKT-mediated BRAF phosphorylation and suggesting that disruption ofAKT-induced BRAF inhibition can play a role in malignant transformation, first report of mutations documenting this interaction in human cancers.